Enterprise Value

264.8M

Cash

175.3M

Avg Qtr Burn

-29.35M

Short % of Float

9.98%

Insider Ownership

0.78%

Institutional Own.

86.41%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ganaxolone (ZTALMY) Details
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder

Approved

Quarterly sales

Ganaxolone Details
Tuberous sclerosis complex

Phase 3

Data readout

Ganaxolone Details
Epilepsy, Refractory Status Epilepticus

Big Mover™

Susp. Mover™

Phase 3

Data readout

Ganaxolone Details
Established Status Epilepticus

Phase 2

Data readout

Phase 1

Data readout